(NASDAQ: IOVA) Iovance Biotherapeutics's forecast annual revenue growth rate of 34.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Iovance Biotherapeutics's revenue in 2025 is $250,425,000.On average, 14 Wall Street analysts forecast IOVA's revenue for 2025 to be $104,823,362,158, with the lowest IOVA revenue forecast at $97,646,181,261, and the highest IOVA revenue forecast at $112,540,419,495. On average, 14 Wall Street analysts forecast IOVA's revenue for 2026 to be $168,612,145,258, with the lowest IOVA revenue forecast at $132,269,727,604, and the highest IOVA revenue forecast at $225,247,565,537.
In 2027, IOVA is forecast to generate $246,822,774,707 in revenue, with the lowest revenue forecast at $184,788,590,035 and the highest revenue forecast at $299,690,968,952.